Published in Arthritis Rheum on September 01, 2001
Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther (2005) 1.52
Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis (2003) 1.49
Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis (2006) 1.39
Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis (2010) 1.19
Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther (2004) 1.09
Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Res Ther (2009) 1.06
Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int (2010) 1.05
VEGF and imaging of vessels in rheumatoid arthritis. Arthritis Res (2002) 1.03
Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha. J Autoimmune Dis (2006) 0.86
Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis. Arthritis Res Ther (2014) 0.84
Recent findings on the role of gelatinases (matrix metalloproteinase-2 and -9) in osteoarthritis. Adv Orthop (2012) 0.84
Angiogenic and inflammatory properties of psoriatic arthritis. ISRN Dermatol (2013) 0.83
Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep (2011) 0.80
What makes psoriatic and rheumatoid arthritis so different? RMD Open (2015) 0.80
Cellular and molecular perspectives in rheumatoid arthritis. Semin Immunopathol (2017) 0.79
Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis. Open Rheumatol J (2011) 0.79
Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis. Clin Rheumatol (2015) 0.77
In vitro effects of platelet-rich gel supernatants on histology and chondrocyte apoptosis scores, hyaluronan release and gene expression of equine cartilage explants challenged with lipopolysaccharide. BMC Vet Res (2016) 0.77
Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis. Int J Biomed Sci (2013) 0.75
Angiogenesis Dysregulation in Psoriatic Arthritis: Molecular Mechanisms. Biomed Res Int (2017) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM (1994) 5.23
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.83
The cryb mutation identifies cryptochrome as a circadian photoreceptor in Drosophila. Cell (1998) 4.81
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Classification of inflammatory arthritis by enthesitis. Lancet (1998) 4.48
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum (2008) 4.25
Generalised bone loss in patients with early rheumatoid arthritis. Lancet (1994) 3.93
The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum (2000) 3.85
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis (2005) 3.25
Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum (2006) 3.03
Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries. Ann Rheum Dis (2004) 2.95
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum (1994) 2.74
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) (2001) 2.52
Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum (1998) 2.51
Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum (2001) 2.49
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Stopping time: the genetics of fly and mouse circadian clocks. Annu Rev Neurosci (2001) 2.44
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol (1997) 2.30
How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS) Rheumatology (Oxford) (2000) 2.21
Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. Clin Exp Immunol (1984) 2.17
Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis (2002) 2.11
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2010) 2.09
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
Effect of vitamin D receptor gene alleles on bone loss in early rheumatoid arthritis. J Rheumatol (1998) 2.05
Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ (1996) 2.04
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis (2008) 2.01
Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol (1998) 1.97
Prescribing in the UK. Lancet (2001) 1.93
An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis (2005) 1.89
Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest (1997) 1.89
Subpopulations of primed T helper cells in rheumatoid arthritis. Arthritis Rheum (1993) 1.88
Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis (2008) 1.86
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
An anatomical explanation for good-prognosis rheumatoid arthritis. Lancet (1999) 1.84
Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis (2004) 1.82
Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum (2007) 1.80
Classical versus non-renal Wegener's granulomatosis. Q J Med (1994) 1.79
Targeted therapies in rheumatoid arthritis: the need for action. Rheumatology (Oxford) (1999) 1.78
The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum (1999) 1.78
Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum (1999) 1.77
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis. Arthritis Rheum (1987) 1.70
D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol (1984) 1.69
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum (1999) 1.65
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Abnormal sulphur oxidation in systemic lupus erythematosus. Lancet (1992) 1.62
Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford) (2003) 1.62
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Acute aortitis and aortic incompetence due to systemic rheumatological disorders. Int J Cardiol (1991) 1.59
Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum (2008) 1.58
Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) (2005) 1.55
The "enthesis organ" concept: why enthesopathies may not present as focal insertional disorders. Arthritis Rheum (2004) 1.54
Rheumatological ultrasound. Rheumatology (Oxford) (2003) 1.54
Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis (2013) 1.53
A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis (2014) 1.52
Pelvic insufficiency fractures in rheumatoid arthritis. Br J Rheumatol (1993) 1.52
Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum (1996) 1.52
A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. J Rheumatol (2001) 1.51
The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy. Rheumatology (Oxford) (2003) 1.50
Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis (2003) 1.49
Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford) (2008) 1.48
Resistant rheumatoid arthritis clinics- a necessary development? Rheumatology (Oxford) (2000) 1.48
Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum (1994) 1.48
Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis (2009) 1.47
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
RFX1 is identical to enhancer factor C and functions as a transactivator of the hepatitis B virus enhancer. Mol Cell Biol (1993) 1.46
Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis (2004) 1.46
RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J (1997) 1.45
Granisetron (Kytril) suppresses methotrexate-induced nausea and vomiting among patients with inflammatory arthritis and is superior to prochlorperazine (Stemetil). Rheumatology (Oxford) (1999) 1.45
Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: a comparison with arthroscopy and clinical examination. Arthritis Rheum (2004) 1.45
EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis. Ann Rheum Dis (2005) 1.44
The case for classification of polymyalgia rheumatica and remitting seronegative symmetrical synovitis with pitting edema as primarily capsular/entheseal based pathologies. J Rheumatol (2000) 1.44
The current status of ultrasonography in rheumatology. Rheumatology (Oxford) (1999) 1.44
An infectious myocarditis syndrome affecting late-term and neonatal piglets. Aust Vet J (2004) 1.44